Trial Profile
An Phase 1b Study of the Safety, Pharmacokinetics and Antiretroviral Activity of the Combination of 3BNC117 and 10-1074 in HIV-infected Individuals
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Teropavimab (Primary) ; Zinlirvimab (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 09 Jan 2020 According to Gilead Sciences media release, that the company has licensed The Rockefeller Universitys portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074.
- 14 Nov 2018 New trial record